Radiolabeled Liposomes via Chelating Agent Mediators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for labeling liposomes with radionuclides result in variable and unstable binding, leading to inaccurate biodistribution data due to weak radionuclide attachment and inefficient entrapment of water-soluble radionuclides.
Innovation Solution
Development of radiolabeled compounds containing specific radionuclides like technetium or rhenium, which form stable complexes with liposomes, ensuring high radionuclide incorporation and retention through specific ligand systems and pH gradients, enhancing the stability and targeting of liposomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional radionuclides are used to label liposomes, then the labeling process is simple, but the binding is weak and radionuclides leach from the liposome
Solution Approach 1:
The patent introduces a chelating agent as an intermediary that mediates between the radionuclide and the liposome. The chelating agent forms stable complexes with radionuclides (such as 99mTc, 186Re, or 188Re) and incorporates these complexes into the liposome structure, preventing direct weak binding while maintaining ease of labeling through standardized chelation chemistry
Solution Approach 2:
The invention creates a composite structure where radionuclides are not merely attached to but are integrated into the liposome through chelating agents. This composite approach combines the liposome's biocompatibility with the chelating agent's strong radionuclide binding capability, resulting in a stable radiolabeled liposome that maintains both simplicity of manufacture and high binding stability
2Ease of manufacture
If water-soluble radionuclides are entrapped during liposome manufacturing, then the process is straightforward, but the entrapment efficiency is low
Solution Approach 1:
The patent applies preliminary action by pre-forming stable radionuclide-chelating agent complexes before liposome incorporation. This pre-complexation ensures that the radionuclide is already bound to a stabilizing agent, dramatically improving entrapment efficiency during the liposome manufacturing process while maintaining procedural simplicity
Solution Approach 2:
The invention utilizes parameter changes by adjusting the chemical state of the radionuclide from a free water-soluble form to a chelated complex form. This parameter change (from free ion to coordinated complex) fundamentally alters the radionuclide's interaction with the liposome, enabling high-efficiency entrapment during standard manufacturing without requiring specialized equipment or complex procedures
3Ease of operation
If radionuclides are weakly bound to liposomes, then the labeling is easy to perform, but the biodistribution data becomes inaccurate
Solution Approach 1:
The chelating agent serves as a mediator that ensures strong, specific binding between the radionuclide and the liposome. This intermediary prevents radionuclide leaching during in vivo circulation and imaging, thereby ensuring that the measured biodistribution data accurately reflects the liposome's biological behavior rather than radionuclide dissociation artifacts
Solution Approach 2:
The patent extracts the binding function from the simple physical attachment process and replaces it with a specific chemical interaction through the chelating agent. This extraction of the binding mechanism ensures that radionuclides remain firmly attached to the liposome throughout the imaging process, guaranteeing accurate biodistribution measurements while preserving ease of operation through standardized chelation protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in stable, long-lasting radiolabeled liposomes with improved biodistribution and retention, allowing for accurate imaging and potential therapeutic applications by maintaining high radionuclide activity within liposomes.
Implementation Method 1
compounds containing a radionuclide useful in the formation of stable, radiolabeled liposomes
Implementation Method 2
ensuring high radionuclide incorporation and retention through specific ligand systems and pH gradients
Data Source
AI summary
The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.